Clinical trials: Oral Chemotherapy
Nasopharyngeal Neoplasms
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma having failed one to two previous regimens, including…
- Trial name
- NCT02269943
- Testing
- CC-486
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 36 people
- Sponsor
- Celgene
Non Squamous Non Small Cell Lung
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
The present trial will be performed to evaluate whether SHR1020 in combination with docetaxel in patients with Local Advanced or Metastatic or recurrent Non Squamous NSCLC is more effective as compared to placebo in combination…
- Trial name
- NCT02766140
- Testing
- SHR1020 plus Docetaxel
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gout
Febuxostat Versus Allopurinol Control Trial in Subjects With Gout
The purpose of this study is to evaluate the safety and efficacy of febuxostat, once daily (QD), versus allopurinol in subjects with gout.
- Trial name
- FACT (NCT00102440)
- Testing
- Febuxostat, Allopurinol
- Volunteers
- 760 people
- Sponsor
- Takeda
Pediatric Hypertension
A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension
The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of TAK-536 (azilsartan) in pediatric patients aged 6 to less than 16 years with hypertension.
- Trial name
- NCT02451150
- Testing
- Azilsartan
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Takeda
Head and Neck Cancer, Squamous Cell Carcinoma
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
The NeoScorch HN study is a single institution multisite phase II trial including 3 cohorts of 25 patients each for patients with newly diagnosed locoregionally advanced, histologically confirmed, head and neck cancer eligible…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancer
- Trial name
- (NeoScorch HN) (NCT07209189)
- Testing
- Toripalimab + Chemotherapy, Toripalimab, Chemoradiotherapy or radiation
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nasopharyngeal Carcinoma
Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined Chemotherapy
Radiation induced oral mucositis which may result in reduced quality of life is commonly seen during radiotherapy, especially combined with chemotherapy. This study is a prospective, single center, and exploratory study.
- Trial name
- NCT03647527
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Cancer Hospital
Mucositis, Solid Tumors
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity…
- Conditions
- Mucositis, Solid Tumors, Stomatitis, Head and Neck Cancer
- Trial name
- NCT00101582
- Testing
- palifermin, cisplatin chemotherapy, Radiotherapy
- Volunteers
- 188 people
- Sponsor
- Swedish Orphan Biovitrum
Oral Mucositis, Stem Cell Transplant Complications
Study of a New Medical Device for Oral Mucositis
This is a single-center randomized controlled trial of a new medical device (Bocaliner™) that has been designed to improve the treatment of chemotherapy-induced oral mucositis in patients undergoing cancer treatment.
- Trial name
- MDOM (NCT05104268)
- Testing
- Bocaliner
- Where
- Armenia
- Sponsor
- E2Bio Life Sciences, LLC
Germ Cell Tumor
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed…
- Trial name
- NCT06937866
- Testing
- Zanzalintinib, Etoposide Capsule
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Indiana University
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003956
- Testing
- fluorouracil, leucovorin calcium, lonafarnib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone.
- Trial name
- NCT01339260
- Testing
- Netupitant and Palonosetron, Palonosetron, Dexamethasone
- Where
- 172 sites in United States, Argentina and 13 more
- Volunteers
- 1,455 people
- Sponsor
- Helsinn Healthcare SA
Mucositis Oral, Stem Cell Transplant Complications
Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation.
Chemotherapy-induced mucositis is an important complication after autologous stem cell transplantation. It is mainly responsible for pain and dysphagia requiring opioids and artificial nutrition.
- Trial name
- AutoSelenium (NCT04080622)
- Testing
- Selenium
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
EGFR/ ALK-negative Advanced NSCLC
Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC
To evaluate the efficacy of metronomic chemotherapy combination with tislelizumab in EGFR/ALK-negative advanced NSCLC patients intolerant to first-line standard chemotherapy.
- Trial name
- NCT06260553
- Testing
- tislelizumab and metronomic oral vinorelbine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fujian Cancer Hospital
Carcinoma, Non-Small-Cell Lung, Chemotherapy, Adjuvant
Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection
This study will establish a multi-center, prospective registration database. The included population are stage II and IIIA NSCLC patients undergoing R0 resection and will be scheduled for adjuvant chemotherapy.
- Trial name
- NCT03479294
- Testing
- Shenlingcao Oral Liquid
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Colorectal Neoplasms
Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer
The purpose of this interventional study is to investigate whether there is evidence that panitumumab in combination with XELOX (capecitabine plus oxaliplatin) chemotherapy will safely increase progression-free survival, above…
- Trial name
- VOXEL (NCT00950820)
- Testing
- Oxaliplatin, Capecitabine, Panitumumab, Oxaliplatin, Capecitabine
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- AIO-Studien-gGmbH
Breast Cancer, Gastrointestinal Cancer
Patient Factors Impacting Adherence to Oral Chemotherapy
The purpose of this study is to identify what makes it easier and what makes it harder to take oral chemotherapy.
- Trial name
- NCT01487343
- Testing
- questionnaire and interview
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma
Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00014313
- Testing
- cisplatin, etoposide
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hepatic Impairment, Healthy Volunteers
A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
The purpose of this study is to characterize the single-dose plasma PK of mobocertinib and its active metabolites (AP32960 and AP32914) in participants with moderate and/or severe HI compared to matched-healthy participants with…
- Trial name
- NCT04056468
- Testing
- Mobocertinib
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Autism, Autistic Disorder
Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism
The purpose of this study is to determine if human immunoglobulin given by mouth twice a day is effective in treating the persistent gastrointestinal (GI) problems such as diarrhea, constipation, abdominal pain, and bloating, in…
- Conditions
- Autism, Autistic Disorder, Child Development Disorders, Pervasive, Gastrointestinal Diseases
- Trial name
- NCT00110708
- Testing
- Oralgam (human immunoglobulin)
- Where
- 22 sites in United States
- Volunteers
- 120 people
- Sponsor
- PediaMed Pharmaceuticals
Diabetes Mellitus, Type 2
Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy of fasiglifam (TAK-875) plus metformin compared with sitagliptin plus metformin on glycemic control over a 24-week Treatment Period.
- Trial name
- NCT01834274
- Testing
- Fasiglifam (TAK-875), Sitagliptin, Metformin
- Where
- 104 sites in United States, Argentina and 11 more
- Volunteers
- 96 people
- Sponsor
- Takeda